BOSTON ( TheStreet) -- Welcome 2010! To get the year started, here's a calendar of important, potentially stock-moving biotech events for January:
28th Annual J.P. Morgan Healthcare Conference.
Food and Drug Administration advisory committee meeting for Forest Labs' Bystolic in congestive heart failure.
International Association for the Study of Lung Cancer meeting. Jan. 14
Ilumina (ILMN - Get Report) investor/analyst meeting. Jan. 16
FDA approval decision date for Mannkind's (MNKD) Afresa, an inhaled insulin for diabetes. Jan. 18
FDA approval decision date for OSI Pharmaceuticals' (OSIP) Tarceva in first-line (maintenance) non-small cell lung cancer. Jan. 22
FDA approval decision date for Acorda Therapeutics' (ACOR - Get Report) Amaya for multiple sclerosis Jan. 22-24
American Society for Clinical Oncology Gastrointestinal Cancers Symposium. Important clinical trials with potential data readouts or other biotech events expected in January: Spectrum Pharmaceuticals (SPPI - Get Report) meeting with FDA to discuss complete response letter for colon cancer drug Fusilev. FDA approval decision for Novo Nordisk's (NVO) diabetes drug Victoza. FDA approval decision for Auxillium Pharmaceuticals' (AUXL) Xiaflex for Dupuytren's Contracture. (With Pfizer (PFE) as marketing partner.) Synta Pharmaceuticals (SNTA) --
Results from a phase II study of apilimod in rheumatoid arthritis. -- Reported by Adam Feuerstein in Boston.